Osteopontin induces mitochondrial biogenesis in deadherent cancer cells: Study
A new research paper was published in Oncotarget is titled, "Osteopontin induces mitochondrial biogenesis in deadherent cancer cells."
Dec 4, 2023
0
0
A new research paper was published in Oncotarget is titled, "Osteopontin induces mitochondrial biogenesis in deadherent cancer cells."
Dec 4, 2023
0
0
A new editorial paper has been published in Oncoscience, titled, "Be mindful of potential pitfalls when using the Cre-LoxP system in cancer research."
Dec 4, 2023
0
0
Researchers at Dana-Farber Cancer Institute have developed a promising new drug candidate, EAI-432, to treat non-small cell lung cancers (NSCLC)driven by mutations in the EGFR gene, particularly the L858R mutation which is ...
Nov 30, 2023
0
39
As cancers grow and spread in the human body, they tend to become more aggressive over time, and this can accelerate during treatment as they develop resistance to drugs. In prostate cancers, some evolve into a rare, treatment-resistant ...
Nov 29, 2023
0
68
The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer for which licensed drugs could be clinically trialed to find out if they could treat the disease. The ...
Nov 29, 2023
0
0
Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway. The findings may lead to a new approach for colorectal cancer ...
Nov 29, 2023
0
0
A new editorial paper titled "The double-edge sword of CRISPR application for in vivo studies" has been published inOncotarget.
Nov 28, 2023
0
0
Greater adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations—which encourage a healthy lifestyle—is associated with a lower risk of all cancers ...
Nov 27, 2023
0
0
A review paper titled "Targeting Ras with protein engineering" has been published in Oncotarget.
Nov 27, 2023
0
0
For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new ...
Nov 21, 2023
0
37